Enterprise Value
618.6M
Cash
129.2M
Avg Qtr Burn
-19.48M
Short % of Float
5.18%
Insider Ownership
22.29%
Institutional Own.
44.29%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VTP-300 + Low dose nivolumab Details Hepatitis B | Phase 2b Data readout | |
Phase 2a Data readout | ||
Imdusiran +NA therapy +VTP-300 Details Hepatitis B | Phase 2a Data readout | |
Imdusiran +NA therapy +IFN Details Hepatitis B | Phase 2a Update | |
AB-101 Details Hepatitis B | Phase 1 Data readout | |
AB-729-001 Details Hepatitis B | Phase 1a Update | |
AB-836 (capsid inhibitor) Details Hepatitis B | Failed Discontinued | |
AB-161 (Oral RNA destabilizer) Details Hepatitis B | Failed Discontinued |